Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuanyuan Yu

Showing results (411-420 of 433) with videos related to

Pageof 44
Sort By:
Journal of Ethnopharmacology|June 25, 2021
Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathwayChuangpeng Shen, Zhisen Pan, Shuangcheng Wu, et al.
Journal of Ethnopharmacology|July 21, 2025
Corrigendum to "Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway" [J. Ethnopharmacol. 279 (2021) 114340]Chuangpeng Shen, Zhisen Pan, Shuangcheng Wu, et al.
Journal of Orthopaedic Translation|July 15, 2024
Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectivesTao Xiaohui, Luyao Wang, Xin Yang, et al.
Theranostics|April 22, 2024
HDAC6-dependent deacetylation of NGF dictates its ubiquitination and maintains primordial follicle dormancyTuo Zhang, Yuntong Tong, Rengguang Zhu, et al.
The New England Journal of Medicine|April 4, 2020
Timing of Endoscopy for Acute Upper Gastrointestinal BleedingJames Y W Lau, Yuanyuan Yu, Raymond S Y Tang, et al.
Journal of Gastroenterology and Hepatology|May 28, 2026
Double EUS-Bypass Versus Conventional Endoscopic Strategies for Concurrent Malignant Gastric Outlet and Biliary ObstructionShanshan Shen, Shuang Nie, Jiaqi Shi, et al.
Bone Research|April 24, 2026
Osteoblastic sclerostin loop3-LRP4 interaction required by sclerostin to inhibit bone formationLuyao Wang, Xiaohui Tao, Hewen Jiang, et al.
Nature Communications|July 22, 2022
Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formationYuanyuan Yu, Luyao Wang, Shuaijian Ni, et al.
Cell Reports. Medicine|April 24, 2026
Intracellular sclerostin promotes tumor progression and metastasis as a potential therapeutic target in triple-negative breast cancerMeiheng Sun, Hang Luo, Shuangying Qiao, et al.
Theranostics|August 15, 2022
Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta miceLuyao Wang, Yuanyuan Yu, Shuaijian Ni, et al.
Pageof 44

Showing results (411-420 of 433) with videos related to

Sort By:
Pageof 44
Journal of Ethnopharmacology|June 25, 2021
Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathwayChuangpeng Shen, Zhisen Pan, Shuangcheng Wu, et al.
Journal of Ethnopharmacology|July 21, 2025
Corrigendum to "Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway" [J. Ethnopharmacol. 279 (2021) 114340]Chuangpeng Shen, Zhisen Pan, Shuangcheng Wu, et al.
Journal of Orthopaedic Translation|July 15, 2024
Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectivesTao Xiaohui, Luyao Wang, Xin Yang, et al.
Theranostics|April 22, 2024
HDAC6-dependent deacetylation of NGF dictates its ubiquitination and maintains primordial follicle dormancyTuo Zhang, Yuntong Tong, Rengguang Zhu, et al.
The New England Journal of Medicine|April 4, 2020
Timing of Endoscopy for Acute Upper Gastrointestinal BleedingJames Y W Lau, Yuanyuan Yu, Raymond S Y Tang, et al.
Journal of Gastroenterology and Hepatology|May 28, 2026
Double EUS-Bypass Versus Conventional Endoscopic Strategies for Concurrent Malignant Gastric Outlet and Biliary ObstructionShanshan Shen, Shuang Nie, Jiaqi Shi, et al.
Bone Research|April 24, 2026
Osteoblastic sclerostin loop3-LRP4 interaction required by sclerostin to inhibit bone formationLuyao Wang, Xiaohui Tao, Hewen Jiang, et al.
Nature Communications|July 22, 2022
Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formationYuanyuan Yu, Luyao Wang, Shuaijian Ni, et al.
Cell Reports. Medicine|April 24, 2026
Intracellular sclerostin promotes tumor progression and metastasis as a potential therapeutic target in triple-negative breast cancerMeiheng Sun, Hang Luo, Shuangying Qiao, et al.
Theranostics|August 15, 2022
Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta miceLuyao Wang, Yuanyuan Yu, Shuaijian Ni, et al.
Pageof 44